leisure time -WSS

leisure time

author：fashion 2025-09-29 14:23:44 - browse：29646

A pharmacist hands a box of Wegovy — first opinion coverage from STAT — Bloomberg photo by George Frey

LONDON — Novo Nordisk said Wednesday that it had started to increase the availability of its blockbuster obesity drug Wegovy for new patients in the United States, after massive demand and a supply crunch had led it to limit doses last May.

The announcement that Novo was making more of its lower-dose starter product available as of this month came as the company reported its 2023 earnings, with sales up by 36% and operating profit up 44% at constant exchange rates, driven by enormous sales of Wegovy and Ozempic, the company’s sister drug for diabetes. The company also projected double-digit growth in sales and operating profit for 2024.

“I am pleased to state that we are now enabling more new U.S. patients to initiate treatment by more than doubling the amount of lower-dose strength Wegovy compared to previous months,” Novo CEO Lars Fruergaard Jørgensen said on a call with reporters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

WSS

The Readout: Gilead, Bernie Sanders, and other pharma news

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Medicare threatens to cut off funding for HCA's Mission hospital

In areas with more Black doctors, Black people live longer

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Senators start work on Medicare physician payment reform

leisure time

leisure time

explore

Trump demands the U.S. pay no more for drugs than other countries … again

What we’ve learned from the Aduhelm mess

What does generative AI mean for health care? We asked experts

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Continuity nursing helped my family in our darkest PICU moments

What should King Charles tell the public about his cancer?

Dobbs anniversary: the lost opportunity of abortion as health care

Gene therapy has helped boys walk. Can scientists keep it that way?

Medical leaders decry Supreme Court decision on affirmative action

How digital tools helped lower hypertension in marginalized patients

hotspot

PhRMA lawsuit over Medicare drug price negotiation tossed

Medicare Advantage proposed rates disappoint insurers

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

The Readout: Gilead, Bernie Sanders, and other pharma news

'Revelatory' study finds a smoking impact that remains after quitting

BioAge raises $170M for combination therapy with Zepbound

Wikipedia

explore

Wikipedia

Wikipedia